% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • t0m.mirabit0 t0m.mirabit0 Dec 15, 2013 10:39 PM Flag

    Lets here from the Serpent Cult on how safe Mirceva is

    Maybe Alpo Expo can do a Stinking Alpha article on the safety profile using the FAERs data.
    Then GeedoubleUPee can remind us of how Omontys' once a month dosing is threatened by Mirceva.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sorry for the spelling. It was a long day. The FDA warns against using the FAERs data but that didn't stop Alpha Expo from using it to trash Omontys. Who does that guy work for? Legal thieves? A competitor?
      I find myself sinking to the low life level of shorts as I sift through this data looking for fault with other ESAs.
      Jagan I've found enough of what I was looking for and that's all I'll say about it till that venomous snake starts his poisonous posting again.
      I'm waiting for the short community to respond to whether or not there have been any deaths of CKD patients on dialysis since Omontys' withdrawal where the anemia medication is suspect. I would say yes, there's no way to avoid it. These are very sick people.
      There is no heroic effort to save patients only greed that brought an american company down. Profiting by using tricks of the greed trade. GWP said it plainly. Their target is a small one product company with limited means of defending itself. GWP's plan is to drain as much cash from the company with voodoo lawsuits. The array of tactics used by shorts will assure Affy will be unable to raise capital to do its own investigation and lose control of its product. That's one fine american we have here folks. And he's not alone.

      • 2 Replies to t0m.mirabit0
      • Tom: thanks for your DD. I did enough of it and that is why I'm sticking around this long.

        I'm unmoved with any of the day to day PPS and don't even bother to look at the PPS.

        I'm pretty confident that the product will come back with a vengeance, and even with a 1 BLN $ sales you will get around 200 MLN $ royalty revenue, around $5 per share in income.

        With 600 MLN $ NOLs they won't be paying any taxes for almost 3 years and they could convert into a Royalty trust.

        GLTA LONGS!

        Sentiment: Strong Buy

      • Hey t0m, that one you sent me, you happen to look into it? From the perspective of buying in i mean. As i told you, i'm already in it. It's like a phase III company again, only you're paying a lot less than you'd be paying for a normal p3.

        That's why i got into it, though that was some time ago, and sub a buck. Same guarantees as a p3 company, which means no guarantees at all, but they do have the advantage imo in that there were no big negatives picked up during prior testing. I take it to be that way since the fda didn't deny the nda outright. One of my "approvables." I don't remember if the fda still had that classification when the company/drug came to my attention.

    • "Methoxy polyethylene glycol-epoetin beta is the active ingredient of a drug marketed by Hoffmann-La Roche under the brand name Mircera."
      Oddly wikipedia doesn't list any side effects caused by Mircera you'd have to dig deeper to find them.
      Could that have something to do with shorting Roche. No incentive to point out faults.

0.0785+0.0043(+5.72%)Jul 29 9:30 AMEDT